OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 43 ADVANCING HEALTH ACCESS AND EQUITY BIOGEN 2021 YEAR IN REVIEW Product availability, health coverage and pricing We recognize that stakeholders see pricing as a material ESG issue for Biogen, and it remains an area of considerable focus for us. We strive to remove barriers to care by offering financial assistance and/or help to secure reimbursement in public and private healthcare programs for patients who are otherwise unable to access our medications. Biogen engages payers throughout the world to gain access for our therapies. In many markets, including those with low GDP per capita, we have developed innovative agreements to meet local needs. It is our strong belief that the decision to treat should be between the physician and the family, without budget concerns. We continue to listen to stakeholders and take their perspectives into account as part of our pricing decisions. We regularly review our pricing strategy and prioritize patient access to our therapies. Value- based contracts, which we have engaged in, are designed to align the price of our therapies to the value they deliver to patients, providers and society. We are transparent about our Pricing Principles . In 2021, we continued to make progress on product availability and coverage for patients in need. Alzheimer’s disease We have taken actions to improve patient access to ADUHELM®. To avoid any treatment interruptions following the Centers for Medicare & Medicaid Services (CMS) decision, Biogen initiated a program for all U.S. patients who began treatment on or before April 7, 2022, making them eligible to receive ADUHELM at no cost for the duration of their treatment or for the duration of the program. MS With MS treatments, we introduced improved product formulations that offer benefits to patients, HCPs and healthcare systems, without increasing our product pricing. In 2021, China’s National Medical Products Administration approved two treatments for MS patients, TECFIDERA® and FAMPYRA®. In China, MS is considered a rare disease. While MS is the second most common cause of non-traumatic neurological disability in young adults, only 10% of the population diagnosed with MS is being treated according to the standard of care with disease-modifying therapy. These approvals bring new treatment options to people in China living with relapsing MS and facing walking challenges due to MS, and continue to expand Biogen’s presence in the country. For MS treatment TYSABRI, we achieved national reimbursement in 22 countries within nine months after approval, including for subcutaneous administration, so more patients can benefit from this improved treatment. Also in 2021 SPINRAZA entered China’s national reimbursement drug list (NRDL), the first high-value rare disease drug included in NRDL. As of early 2022, China had become the premier market for SPINRAZA, serving over 2,000 patients across 30 of the country’s provinces, cities and autonomous regions. SMA SMA patients have access to SPINRAZA in 65 countries – either via formal reimbursement, individual reimbursement or named-patient sales programs – including low- and middle-income countries. – In Brazil in 2021, CONITEC, the country’s health technology assessment (HTA) agency, expanded their initial reimbursement decision for SPINRAZA in order to cover Type 2 patients as well. The process started two years ago and CONITEC’S HTA process for SPINRAZA involved a record-setting input, with 1,500% more public responses than the closest comparison. The Ministry of Health held a publicly broadcasted four-hour hearing where health managers, researchers, health professionals, patient and caregiver representatives, and the pharmaceutical industry voiced support. Negotiation of a risk-sharing agreement may enable patients to receive access to SPINRAZA through a government program. – In India, we were able to advance our SPINRAZA Individual Patient Humanitarian Aid Access Program (SIPHAP). Developed in collaboration with Direct Relief, SIPHAP provides SPINRAZA free of charge to patients selected by an independent committee of medical experts. SIPHAP initially launched with 24 patients across four public hospitals, and expanded to a total of 211 patients across 14 public hospitals in 2021.